注射用炎琥宁联合磷酸奥司他韦颗粒治疗小儿病毒性肺炎的效果(1)
摘要：目的 探討注射用炎琥宁联合磷酸奥司他韦颗粒治疗小儿病毒性肺炎的临床效果。方法 选取2018年1月～2019年10月本院儿科收治的68例病毒性肺炎患儿为研究对象，按照随机数字表法分成对照组与观察组，各34例。对照组给予磷酸奥司他韦颗粒治疗，观察组给予注射用炎琥宁联合磷酸奥司他韦颗粒治疗，比较两组临床症状消失时间、治疗前后炎性标志物[肿瘤坏死因子TNF-α、C反应蛋白(CRP)及白细胞介素6(IL-6)水平]、总有效率及药物不良反应发生情况。结果 观察组的临床症状(热退、咳嗽与啰音)消失时间短于对照组(P<0.05);治疗后观察组炎性标志物均低于对照组(P<0.05);观察组总有效率(94.12%)高于对照组(79.41%)(P<0.05)。两组药物不良反应发生率比较，差异无统计学意义(P>0.05)。结论 注射用炎琥宁联合磷酸奥司他韦颗粒治疗小儿病毒性肺炎有助于缓解临床症状，降低血清炎性指标，提高疗效，安全性高，无严重药物不良反应，值得联合应用。
关键词：炎琥宁;磷酸奥司他韦;小儿病毒性肺炎
中图分类号：R725.6 文献标识码：A DOI：10.3969/j.issn.1006-1959.2020.17.043
文章编号：1006-1959(2020)17-0148-03
Abstract：Objective To explore the clinical effect of Yanhuning for injection combined with oseltamivir phosphate particles in the treatment of children with viral pneumonia.Methods A total of 68 children with viral pneumonia admitted to the Department of Pediatrics of our hospital from January 2018 to October 2019 were selected as the research objects， and were divided into a control group and an observation group according to the random number table method， with 34 cases in each group. The control group was treated with oseltamivir phosphate granules， and the observation group was treated with Yanhuning for injection combined with oseltamivir phosphate granules. The disappearance time of clinical symptoms and the inflammatory markers before and after treatment were compared between the two groups [tumor necrosis factor TNF-α， C-reactive protein (CRP) and interleukin 6 (IL-6) levels]， total effective rate and occurrence of adverse drug reactions.Results The disappearance time of clinical symptoms (feeling， cough and rales) in the observation group was shorter than that in the control group(P<0.05); after treatment， the inflammatory markers in the observation group were lower than those in the control group(P<0.05); the total effective rate (94.12%) of the observation group was higher than that of the control group (79.41%)(P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups (P>0.05).Conclusion Yanhuning for injection combined with oseltamivir phosphate particles in the treatment of children with viral pneumonia could help relieve clinical symptoms， reduced serum inflammatory indicators， improved efficacy， high safety， and no serious adverse drug reactions. It is worthy of combined application., 百拇医药(林万鸿 曾宪辉 伍清龙)
关键词：炎琥宁;磷酸奥司他韦;小儿病毒性肺炎
中图分类号：R725.6 文献标识码：A DOI：10.3969/j.issn.1006-1959.2020.17.043
文章编号：1006-1959(2020)17-0148-03
Abstract：Objective To explore the clinical effect of Yanhuning for injection combined with oseltamivir phosphate particles in the treatment of children with viral pneumonia.Methods A total of 68 children with viral pneumonia admitted to the Department of Pediatrics of our hospital from January 2018 to October 2019 were selected as the research objects， and were divided into a control group and an observation group according to the random number table method， with 34 cases in each group. The control group was treated with oseltamivir phosphate granules， and the observation group was treated with Yanhuning for injection combined with oseltamivir phosphate granules. The disappearance time of clinical symptoms and the inflammatory markers before and after treatment were compared between the two groups [tumor necrosis factor TNF-α， C-reactive protein (CRP) and interleukin 6 (IL-6) levels]， total effective rate and occurrence of adverse drug reactions.Results The disappearance time of clinical symptoms (feeling， cough and rales) in the observation group was shorter than that in the control group(P<0.05); after treatment， the inflammatory markers in the observation group were lower than those in the control group(P<0.05); the total effective rate (94.12%) of the observation group was higher than that of the control group (79.41%)(P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups (P>0.05).Conclusion Yanhuning for injection combined with oseltamivir phosphate particles in the treatment of children with viral pneumonia could help relieve clinical symptoms， reduced serum inflammatory indicators， improved efficacy， high safety， and no serious adverse drug reactions. It is worthy of combined application., 百拇医药(林万鸿 曾宪辉 伍清龙)